Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA.

Magarian-Blander J, Domenech N, Finn OJ.

Ann N Y Acad Sci. 1993 Aug 12;690:231-43.

PMID:
7690213
2.

Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr, Finn OJ.

Cancer Res. 1991 Jun 1;51(11):2908-16.

5.

Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition.

Bu D, Domenech N, Lewis J, Taylor-Papadimitriou J, Finn OJ.

J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):127-35.

PMID:
7506575
6.

Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.

Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ.

J Immunol. 1993 Oct 1;151(7):3693-703.

PMID:
7690810
7.

Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells.

Magarian-Blander J, Hughey RP, Kinlough C, Poland PA, Finn OJ.

Glycoconj J. 1996 Oct;13(5):749-56.

PMID:
8910002
8.
9.

Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.

Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W.

Blood. 1999 Jun 15;93(12):4309-17.

10.

Functional and molecular analysis of T cell receptors used by pancreatic- and breast tumor- (mucin-) specific cytotoxic T cells.

Kirii Y, Magarian-Blander J, Alter MD, Kotera Y, Finn OJ.

J Immunother. 1998 May;21(3):188-97.

PMID:
9610910
11.

Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.

Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K.

Int Immunol. 1997 May;9(5):791-8.

PMID:
9184925
12.

Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.

Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A.

J Immunol. 1994 Sep 1;153(5):2102-9.

PMID:
8051415
13.

Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.

Irimura T, Denda K, Iida Si, Takeuchi H, Kato K.

J Biochem. 1999 Dec;126(6):975-85. Review.

14.

The breast tumor-associated epitope defined by monoclonal antibody 3E1.2 is an O-linked mucin carbohydrate containing N-glycolylneuraminic acid.

Devine PL, Clark BA, Birrell GW, Layton GT, Ward BG, Alewood PF, McKenzie IF.

Cancer Res. 1991 Nov 1;51(21):5826-36.

15.

[New mucin core protein genes and their clinical application].

Imai K.

Hokkaido Igaku Zasshi. 1996 Mar;71(2):139-43. Review. Japanese.

PMID:
8641670
16.

Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin.

Doménech N, Henderson RA, Finn OJ.

J Immunol. 1995 Nov 15;155(10):4766-74.

PMID:
7594478
17.

Mucin-1-related T cell infiltration in colorectal carcinoma.

Mulder WM, Stukart MJ, de Windt E, Wagstaff J, Scheper RJ, Bloemena E.

Cancer Immunol Immunother. 1996 Jul;42(6):351-6.

PMID:
8830738
18.
19.

Making the most of mucin: a novel target for tumor immunotherapy.

Barratt-Boyes SM.

Cancer Immunol Immunother. 1996 Nov;43(3):142-51. Review.

PMID:
9001567
20.

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF.

Vaccine. 2000 Apr 3;18(19):2059-71.

PMID:
10706970

Supplemental Content

Support Center